BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 25716461)

  • 1. Treatment of invasive silent somatotroph pituitary adenoma with temozolomide. Report of a case and review of the literature.
    Ghazi AA; Rotondo F; Kovacs K; Amirbaigloo A; Syro LV; Fathalla H; Di Ieva A; Cusimano MD
    Endocr Pathol; 2015 May; 26(2):135-9. PubMed ID: 25716461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of temozolomide in the treatment of a patient with a pure silent pituitary somatotroph carcinoma.
    Vieira Neto L; Chimelli L; Pereira PJ; Gasparetto EL; Bines J; Wildemberg LE; Gadelha MR
    Endocr Pract; 2013; 19(6):e145-9. PubMed ID: 23807517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of temozolomide in aggressive pituitary tumors: case report.
    Mohammed S; Kovacs K; Mason W; Smyth H; Cusimano MD
    Neurosurgery; 2009 Apr; 64(4):E773-4; discussion E774. PubMed ID: 19349807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.
    Losa M; Bogazzi F; Cannavo S; Ceccato F; Curtò L; De Marinis L; Iacovazzo D; Lombardi G; Mantovani G; Mazza E; Minniti G; Nizzoli M; Reni M; Scaroni C
    J Neurooncol; 2016 Feb; 126(3):519-25. PubMed ID: 26614517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temozolomide therapy for aggressive pituitary Crooke's cell corticotropinoma causing Cushing's Disease - a case report with literature review.
    Gilis-Januszewska A; Wilusz M; Pantofliński J; Turek-Jabrocka R; Sokołowski G; Sowa-Staszczak A; Kluczyński Ł; Pach D; Zieliński G; Hubalewska-Dydejczyk A
    Endokrynol Pol; 2018; 69(3):306-312. PubMed ID: 29319131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma.
    Syro LV; Scheithauer BW; Ortiz LD; Fadul CE; Horvath E; Rotondo F; Kovacs K
    Hormones (Athens); 2009; 8(4):303-6. PubMed ID: 20045804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment.
    Campderá M; Palacios N; Aller J; Magallón R; Martín P; Saucedo G; Lilienfeld H; Estrada J
    Pituitary; 2016 Apr; 19(2):158-66. PubMed ID: 26586560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases.
    Losa M; Mazza E; Terreni MR; McCormack A; Gill AJ; Motta M; Cangi MG; Talarico A; Mortini P; Reni M
    Eur J Endocrinol; 2010 Dec; 163(6):843-51. PubMed ID: 20870708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy.
    Moshkin O; Syro LV; Scheithauer BW; Ortiz LD; Fadul CE; Uribe H; Gonzalez R; Cusimano M; Horvath E; Rotondo F; Kovacs K
    Hormones (Athens); 2011; 10(2):162-7. PubMed ID: 21724542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temozolomide in aggressive pituitary adenomas and carcinomas.
    Ortiz LD; Syro LV; Scheithauer BW; Rotondo F; Uribe H; Fadul CE; Horvath E; Kovacs K
    Clinics (Sao Paulo); 2012; 67 Suppl 1(Suppl 1):119-23. PubMed ID: 22584716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of pituitary neoplasms with temozolomide: a review.
    Syro LV; Ortiz LD; Scheithauer BW; Lloyd R; Lau Q; Gonzalez R; Uribe H; Cusimano M; Kovacs K; Horvath E
    Cancer; 2011 Feb; 117(3):454-62. PubMed ID: 20845485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
    Bengtsson D; Schrøder HD; Andersen M; Maiter D; Berinder K; Feldt Rasmussen U; Rasmussen ÅK; Johannsson G; Hoybye C; van der Lely AJ; Petersson M; Ragnarsson O; Burman P
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1689-98. PubMed ID: 25646794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review.
    Curtò L; Torre ML; Ferraù F; Pitini V; Altavilla G; Granata F; Longo M; Hofland LJ; Trimarchi F; Cannavò S
    ScientificWorldJournal; 2010 Nov; 10():2132-8. PubMed ID: 21057727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center.
    Ceccato F; Lombardi G; Manara R; Emanuelli E; Denaro L; Milanese L; Gardiman MP; Bertorelle R; Scanarini M; D'Avella D; Occhi G; Boscaro M; Zagonel V; Scaroni C
    J Neurooncol; 2015 Mar; 122(1):189-96. PubMed ID: 25555563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-uniform response to temozolomide therapy in a pituitary gonadotroph adenoma.
    Ersen A; Syro LV; Penagos L; Uribe H; Scheithauer BW; Ortiz LD; Rotondo F; Horvath E; Kovacs K
    Can J Neurol Sci; 2012 Sep; 39(5):683-5. PubMed ID: 23066557
    [No Abstract]   [Full Text] [Related]  

  • 16. Refractory pituitary adenoma: a novel classification for pituitary tumors.
    Dai C; Feng M; Liu X; Ma S; Sun B; Bao X; Yao Y; Deng K; Wang Y; Xing B; Lian W; Zhong D; Ma W; Wang R
    Oncotarget; 2016 Dec; 7(50):83657-83668. PubMed ID: 27845901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors.
    Hirohata T; Asano K; Ogawa Y; Takano S; Amano K; Isozaki O; Iwai Y; Sakata K; Fukuhara N; Nishioka H; Yamada S; Fujio S; Arita K; Takano K; Tominaga A; Hizuka N; Ikeda H; Osamura RY; Tahara S; Ishii Y; Kawamata T; Shimatsu A; Teramoto A; Matsuno A
    J Clin Endocrinol Metab; 2013 Mar; 98(3):1130-6. PubMed ID: 23365123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide.
    Matsuno A; Murakami M; Hoya K; Yamada SM; Miyamoto S; Yamada S; Son JH; Nishido H; Ide F; Nagashima H; Sugaya M; Hirohata T; Mizutani A; Okinaga H; Ishii Y; Tahara S; Teramoto A; Osamura RY
    Med Mol Morphol; 2014 Mar; 47(1):1-7. PubMed ID: 23955641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of pituitary carcinomas and atypical pituitary adenomas: a review.
    Hirohata T; Ishii Y; Matsuno A
    Neurol Med Chir (Tokyo); 2014; 54(12):966-73. PubMed ID: 25446382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple cerebral hemorrhagic foci from metastases during temozolomide treatment in a patient with corticotroph pituitary carcinoma.
    Mendola M; Passeri E; Ambrosi B; Corbetta S
    J Clin Endocrinol Metab; 2014 Aug; 99(8):2623-4. PubMed ID: 24823463
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.